Contacts
Info
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science,...
show more
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!
show less
Episodes & Posts
Episodes
Posts
Transcribed
24 SEP 2025 · https://www.linkedin.com/in/bryan-kobel-330a197/ decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of https://tcbiopharm.com/, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.
Transcribed
17 SEP 2025 · Science will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing on their talent pool with pay off in terms of company success. She joins Ammon Rivera in this episode to tell us what it takes exactly to build an excellent company culture in a biotech company and why the act of building one will give any business its biggest ROI. Tune in!
Transcribed
10 SEP 2025 · There isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is https://www.qualigeninc.com/. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302.  Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, https://www.linkedin.com/in/drbiotech/, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therapeutics when it comes to killing these cancer cells. Let's all come together and stop cancer.
Transcribed
3 SEP 2025 · https://www.qualigeninc.com/ is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews https://www.linkedin.com/in/wwwlinkedinamybroidrick, the firm’s President and Chief Strategy Officer. She shares what she brings to the table in the company’s transition from a preclinical stage company to a brand new business venture. She also talks about her deep love for market research, her career’s pivotal and most fulfilling moments, and how she deals with negativity.
Transcribed
27 AUG 2025 · AI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granularity, allowing them to identify the right targets to go after. In this interview, Noam shares his knowledge on reprogramming the immune system for better diagnosis and treatment. He shares his amazing team and how they make patient’s lives easier and meaningful. Tune in to learn more about immunotherapies!
Transcribed
20 AUG 2025 · Social anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be stopped. But how can it be stopped? https://www.linkedin.com/in/shawnsingh/, the CEO and Director of https://www.vistagen.com/, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for social anxiety. Join Ammon Rivera as he talks to Shawn Singh about the PH94B nasal spray. Find out how it works and how far along they are in the process. If they get approved, VistaGen has the opportunity to be the first FDA-approved acute treatment for adults with social anxiety disorder. Discover how VistaGen is going beyond the current standard of care for anxiety, depression, and CNS disorders.Â
Transcribed
13 AUG 2025 · Companies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with https://www.linkedin.com/in/danielteper/, Co-Founder and CEO of https://www.cytoviatx.com/daniel-teper, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions amidst recent news of a special purpose acquisition with Isleworth Healthcare Corporation. There’s much to learn from this episode, both in medicine and economics.
Transcribed
6 AUG 2025 · Cell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is where the biotech company, https://cyclacel.com/ comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to https://www.linkedin.com/in/spiro-rombotis-526807/?originalSubdomain=uk about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases. Ammon and Spiro go over the use of Cyclin-dependent Kinase and its role in the cell cycle. Spiro also talks about Cyclacel's pipeline and drug candidates. They also go through discussion strategy, the drug approval process, and what it means to fail fast.
Transcribed
30 JUL 2025 · Have you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. https://www.linkedin.com/in/brian-culley-7b219a1/ is one of the leaders in this field. He is the CEO of https://lineagecell.com/, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and where they’re going from there.
Transcribed
23 JUL 2025 · The biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits down with two-peat guest, https://www.linkedin.com/in/guillermomorales/, CEO of https://innoventyx.com/. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Guillermo also shares his experience learning and re-learning the science in both languages and how it impacts communication. Don’t miss out on their enlightening conversation by tuning in!
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science,...
show more
Increase your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development, safety/PV and more! We address how each function plays an important role in the drug approval process. We also discuss the people that make up these departments. Get ready to hear about cutting edge development and the people who make it happen!
show less
Information
| Author | TADF |
| Organization | TADF |
| Categories | Life Sciences , Investing , Management |
| Website | www.spreaker.com |
| booking@podgo.io |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
